Soligenix (NASDAQ:SNGX) Stock Turns Volatile After The Key Data

September 10, 2021

Soligenix (NASDAQ:SNGX) jumped 11% following the grant of the orphan drug designation from the FDA for its active product candidate hypericin in T-cell lymphoma treatment. The grant expands the company’s prior orphan drug designation for the active ingredient that permitted its uses in cutaneous T-Cell lymphoma treatment. For Soligenix shareholders, this is great news as the designation grant will open up hypericin for a broader market. Besides broader market access,…


Soligenix Inc. (NASDAQ: SNGX) Offers Updates in HyBryte and CiVaX Vaccine Development

July 23, 2021

Soligenix Inc. (NASDAQ: SNGX) has announced its financial results and recent accomplishments for the quarter ended March 31, 2021.  HyBruyte receives “Innovation Passport.” HyBryte (hypericin) was granted an “Innovation Passport” for early-stage CTCL treatment in adults by the UK’s Innovative Licensing and Access Pathway on May 10, 2021. In addition, on April 28, 2021, the Soligenix confirmed that Oreola Donini, SVP, and Chief Scientific Officer, presented at the Annual Conference…